帕罗西汀合并奎硫平治疗躯体形式障碍的疗效

Comparison study of paroxetine and paroxetine combined with quetiapine in treatment of somatoform disorders

目的探讨帕罗西汀合并奎硫平治疗躯体形式障碍的疗效及安全性。方法58例躯体形式障碍患者随机分为2组,研究组以帕罗西汀合并奎硫平进行治疗,对照组单用帕罗西汀治疗,疗程均为8周。治疗前与治疗第2,8周采用症状自评量表(SCL-90)、汉密尔顿抑郁量表(HAMD)评定临床疗效,副反应量表(TESS)评定不良反应。结果治疗后2组SCL-90、HAMD评分较治疗前减少,差异有显著性(P<0.01)。8周末研究组有效率80%,对照组53.8%,2组差异有显著性(P<0.05)。并且在治疗2周末研究组较对照组见效快,差异有显著性(P<0.05)。2组不良反应均表现较轻,大多出现在治疗早期,经对症治疗逐渐缓解。结论帕罗西汀合并奎硫平治疗躯体形式障碍较单用帕罗西汀疗效好,起效快,且不增加副作用。

Objective To study the clinical effects and safety of paroxetine combined with quetiapine in treatment of somatoform disorders. Methods 56 patients were assigned to paroxetine （ control group, n = 30） and paroxetine combined with quetiapine（ study group, n = 26 ）, and treated for 8 weeks. Before treatment and at the ends of the 2nd and 8th week after treatment, the clinical effects and side effects were assessed with SCL-90, HAMD, TESS. Results The score of SCL-90 and HAMD after the treatment of the study group and control group were lower than before treatment, which had a significant difference （ P〈0.01 ）. At the end of 8th week,effective rates of the study group and control group were respectively 80% and 53.8% ,which had a significant difference（ P 〈 0.05 ）. There was difference in the effective time of drugs of the two groups （ P 〈 0.02）. Side effects of both the two groups were milder, most occurred in the initial stage of treatment and gradually remitted via expectant treatment. Conclusion Paroxetine combined with quetiapine in treatment of somatoform disorders takes effects better and faster than single paroxetine and doesn＇t increase side effects.